1. Atkinson, A.J., Colburn, W.A., DeGruttola, V., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T., Spilker, B.A., Woodcock, J., Zeger, S.L., submitted. Biomarkers and surrogate endpoints in clinical trials: preferred definitions and conceptual framework. J. Am. Med. Ass.
2. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer;Bruno;J. Clin. Oncol.,1998
3. Pharmacologically guided phase I clinical trials based upon preclinical drug development;Collins;J. Natl. Cancer Inst.,1990
4. The pharmacokinetics of the new short-acting opioid remifentanil (GI 87084B) in healthy adult male volunteers;Egan;Anesthesiology,1993
5. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B);Glass;Anesth. Analg.,1993